|
Mar 11
|
Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock
|
|
Mar 10
|
Analyst Estimates: Here's What Brokers Think Of Evolus, Inc. (NASDAQ:EOLS) After Its Full-Year Report
|
|
Mar 9
|
Evolus Full Year 2023 Earnings: In Line With Expectations
|
|
Mar 8
|
Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript
|
|
Mar 8
|
Q4 2023 Evolus Inc Earnings Call
|
|
Mar 8
|
Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024
|
|
Mar 7
|
Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance
|
|
Mar 5
|
11 Best Small Cap Pharma Stocks to Invest In
|
|
Jan 16
|
Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance
|
|
Jan 9
|
Wall Street Analysts See a 133.85% Upside in Evolus, Inc. (EOLS): Can the Stock Really Move This High?
|
|
Dec 20
|
Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe
|
|
Dec 8
|
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Aug 27
|
Insiders Pour Millions Into These 2 Stocks, Analysts Say They Have up to 120% Upside — Here’s Why You Should Pay Attention
|
|
Aug 23
|
Evolus Announces Inducement Grants for New Chief Marketing Officer
|
|
Aug 21
|
Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer
|
|
Jun 29
|
Evolus Launches Nuceiva® (botulinum toxin type A) in Italy
|